Payment overview · 2025
General Payments
$149.04
7 reported records · 4 companies
Healthcare provider profile · identity verified
Marguerite Yao, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHAPEL HILL, NC · NPI 1093030264
Verified facts
What the public records show
CMS Open Payments records show Marguerite Yao, MD received $149.04 in general payments during 2025 across 7 reported records.
Ardelyx, Inc. accounted for 46.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $69.43 | 46.6% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $42.52 | 28.5% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $20.90 | 14.0% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $16.19 | 10.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $149.04 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $69.43 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $42.52 | 2 | 2025 |
Source payment records
|
|||||
| SIMPONI Normalized: simponi |
Biological | Janssen Biotech, Inc. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $16.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 249 | 70 |
| Losartan Potassium | Losartan Potassium | 248 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 184 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 147 | 38 |
| Gabapentin | Gabapentin | 109 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 96 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 27 |
| Omeprazole | Omeprazole | 94 | 30 |
| Simvastatin | Simvastatin | 88 | 25 |
| Trazodone Hcl | Trazodone Hcl | 88 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 26 |
| Metformin Hcl | Metformin Hcl | 83 | 24 |
| Clonazepam | Clonazepam | 79 | 15 |
| Lisinopril | Lisinopril | 78 | 20 |
| Lorazepam | Lorazepam | 77 | 23 |
| Jardiance | Empagliflozin | 76 | 16 |
| Sertraline Hcl | Sertraline Hcl | 68 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 12 |
| Bupropion Xl | Bupropion Hcl | 62 | 18 |
| Eliquis | Apixaban | 60 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | 13 |
| Atenolol | Atenolol | 53 | 14 |
| Alprazolam | Alprazolam | 51 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | suppressed |
| Meloxicam | Meloxicam | 45 | 19 |
| Famotidine | Famotidine | 44 | 11 |
| Furosemide | Furosemide | 43 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 43 | 13 |
| Valacyclovir | Valacyclovir Hcl | 43 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 19 |
| Tramadol Hcl | Tramadol Hcl | 40 | 17 |
| Ozempic | Semaglutide | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 35 | 11 |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | 12 |
| Allopurinol | Allopurinol | 27 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 17 |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Prednisone | Prednisone | 22 | 15 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 16 |
| Telmisartan | Telmisartan | 19 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 18 | 11 |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 12 |
| Glipizide | Glipizide | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $149.04 · 7 records | Ardelyx, Inc. | DUPIXENT, IBSRELA, SIMPONI, SIMPONI ARIA, STELARA, TREMFYA, YUPELRI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Janssen Biotech, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error